There is no question the folks at Abbott (NYSE: ABT) feel good about the FreeStyle Libre. There is also no question that the Street likes the product and there is no question at all that the analysts haven’t a clue about the CGM market. Now before we go any further it’s time to get something straight from a technical definition the Libre is NOT as it is configured a continuous glucose monitor. It does not deliver readings continuously as the patient MUST interact with the device to see a reading. This is a critical difference that all the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.